

Amniotics granted key EU patent for its technology platform

Amniotics (publ) (Nasdaq Stockholm: AMNI) announced today that the European Patent Office (EPO) has approved a patent application for the company's stem cell technology platform, including the product candidate PulmoStem™. This patent, no. EP3886880 B1, "Processes and apparatuses for obtaining amniotic fluid mesenchymal stem cells from amniotic fluid and cells derived thereof", provides Amniotics with exclusive commercial rights in the EU at least until 2040 for the manufacture and use of the neonatal stem cells that Amniotics are developing.

- This EU patent is a strong addition to Amniotics patent portfolio as it covers key concepts including our selection techniques of specific cells and our manufacturing methods that are the basis for Amniotics tissue specific neonatal stem cell technology. The patent includes the product candidate PulmoStem (lung), but is also highly relevant to our other candidates, e.g. CogniStem (brain). We wish to thank our legal associates at Potter Clarkson for making this application successful, says Marcus Larsson, CEO, Amniotics AB.

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amniotics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.

Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.

Amniotics is headquartered in Lund, Sweden.

The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.

Learn more at www.amniotics.com.

Press Release
07 June 2023 19:35:00 CEST



Attachments

[Amniotics granted key EU patent for its technology platform](#)